{
  "resourceType" : "Composition",
  "id" : "399873",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2025-12-11T20:35:21.032Z",
    "profile" : ["http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 399873</b></p><a name=\"399873\"> </a><a name=\"hc399873\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-outcome-measure-report.html\">OutcomeMeasureReport</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/399873\">https://fevir.net/resources/Composition/399873</a></p><p><b>identifier</b>: FEvIR Object Identifier/399873, FEvIR Linking Identifier/NCT03421379-outcome-measure-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 OutcomeMeasureReport}\">Outcome Measure Report</span></p><p><b>date</b>: 2025-12-11 20:35:21+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Outcome Measures Report for NCT03421379</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json.</p>\n</div></td></tr></table></div>"
  },
  "url" : "https://fevir.net/resources/Composition/399873",
  "identifier" : [{
    "type" : {
      "coding" : [{
        "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
        "code" : "ACSN",
        "display" : "Accession ID"
      }],
      "text" : "FEvIR Object Identifier"
    },
    "system" : "https://fevir.net/FOI",
    "value" : "399873",
    "assigner" : {
      "display" : "Computable Publishing LLC"
    }
  },
  {
    "type" : {
      "text" : "FEvIR Linking Identifier"
    },
    "system" : "https://fevir.net/FLI",
    "value" : "NCT03421379-outcome-measure-report",
    "assigner" : {
      "display" : "Computable Publishing LLC"
    }
  }],
  "status" : "final",
  "type" : {
    "coding" : [{
      "system" : "https://fevir.net/resources/CodeSystem/179423",
      "code" : "OutcomeMeasureReport",
      "display" : "OutcomeMeasureReport"
    }],
    "text" : "Outcome Measure Report"
  },
  "date" : "2025-12-11T20:35:21.032Z",
  "author" : [{
    "display" : "[No author listed.]"
  }],
  "title" : "Outcome Measures Report for NCT03421379",
  "custodian" : {
    "reference" : "Organization/118079",
    "type" : "Organization",
    "display" : "Computable Publishing LLC"
  },
  "relatesTo" : [{
    "type" : "cite-as",
    "targetMarkdown" : "Outcome Measures Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399873. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399873. Computable resource at: https://fevir.net/resources/Composition/399873#json."
  }],
  "section" : [{
    "title" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration",
    "focus" : {
      "reference" : "EvidenceVariable/267226",
      "type" : "EvidenceVariable",
      "identifier" : {
        "type" : {
          "text" : "FEvIR Linking Identifier"
        },
        "system" : "https://fevir.net/FLI",
        "value" : "NCT03421379-primaryOutcome-0",
        "assigner" : {
          "display" : "Computable Publishing LLC"
        }
      },
      "display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)"
    },
    "section" : [{
      "title" : "Outcome Measure Population Description",
      "code" : {
        "text" : "OutcomeMeasurePopulationDescription"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participant who completed both treatment visits and had evaluable treatment success data.</div>"
      }
    },
    {
      "title" : "Outcome Measure Reporting Status",
      "code" : {
        "text" : "OutcomeMeasureReportingStatus"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
      }
    },
    {
      "title" : "Outcome Measure Time Frame",
      "code" : {
        "text" : "OutcomeMeasureTimeFrame"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose up to 30 minutes post each glucagon administration</div>"
      }
    },
    {
      "title" : "Outcome Group List",
      "code" : {
        "text" : "OutcomeGroupList"
      },
      "section" : [{
        "title" : "Glucagon Nasal Powder",
        "code" : {
          "text" : "OG000"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
        },
        "entry" : [{
          "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
        }]
      },
      {
        "title" : "Glucagon Hydrochloride Solution",
        "code" : {
          "text" : "OG001"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
        },
        "entry" : [{
          "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
        }]
      }]
    },
    {
      "title" : "Outcome Class List",
      "code" : {
        "text" : "OutcomeClassList"
      },
      "section" : [{
        "title" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)",
        "code" : {
          "coding" : [{
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }]
        },
        "focus" : {
          "reference" : "EvidenceVariable/267226",
          "type" : "EvidenceVariable",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-primaryOutcome-0",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration (NCT03421379)"
        },
        "entry" : [{
          "reference" : "Evidence/267232",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-primaryOutcomeMeasure-0--OG000",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "Evidence/267233",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-primaryOutcomeMeasure-0--OG001",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
        },
        {
          "reference" : "Evidence/267244",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379"
        }]
      }]
    }]
  },
  {
    "title" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
    "focus" : {
      "reference" : "EvidenceVariable/267227",
      "type" : "EvidenceVariable",
      "identifier" : {
        "type" : {
          "text" : "FEvIR Linking Identifier"
        },
        "system" : "https://fevir.net/FLI",
        "value" : "NCT03421379-secondaryOutcome-0",
        "assigner" : {
          "display" : "Computable Publishing LLC"
        }
      },
      "display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
    },
    "section" : [{
      "title" : "Outcome Measure Population Description",
      "code" : {
        "text" : "OutcomeMeasurePopulationDescription"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized patients who receive at least 1 dose of the study drug and have evaluable PD data.</div>"
      }
    },
    {
      "title" : "Outcome Measure Reporting Status",
      "code" : {
        "text" : "OutcomeMeasureReportingStatus"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
      }
    },
    {
      "title" : "Outcome Measure Time Frame",
      "code" : {
        "text" : "OutcomeMeasureTimeFrame"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
      }
    },
    {
      "title" : "Outcome Group List",
      "code" : {
        "text" : "OutcomeGroupList"
      },
      "section" : [{
        "title" : "Glucagon Nasal Powder",
        "code" : {
          "text" : "OG000"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
        },
        "entry" : [{
          "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
        }]
      },
      {
        "title" : "Glucagon Hydrochloride Solution",
        "code" : {
          "text" : "OG001"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
        },
        "entry" : [{
          "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
        }]
      }]
    },
    {
      "title" : "Outcome Class List",
      "code" : {
        "text" : "OutcomeClassList"
      },
      "section" : [{
        "title" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
        "code" : {
          "coding" : [{
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }]
        },
        "focus" : {
          "reference" : "EvidenceVariable/267227",
          "type" : "EvidenceVariable",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcome-0",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
        },
        "entry" : [{
          "reference" : "Evidence/267234",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-0--OG000",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "Evidence/267235",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-0--OG001",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
        }]
      }]
    }]
  },
  {
    "title" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
    "focus" : {
      "reference" : "EvidenceVariable/267228",
      "type" : "EvidenceVariable",
      "identifier" : {
        "type" : {
          "text" : "FEvIR Linking Identifier"
        },
        "system" : "https://fevir.net/FLI",
        "value" : "NCT03421379-secondaryOutcome-1",
        "assigner" : {
          "display" : "Computable Publishing LLC"
        }
      },
      "display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
    },
    "section" : [{
      "title" : "Outcome Measure Population Description",
      "code" : {
        "text" : "OutcomeMeasurePopulationDescription"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PD data.</div>"
      }
    },
    {
      "title" : "Outcome Measure Reporting Status",
      "code" : {
        "text" : "OutcomeMeasureReportingStatus"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
      }
    },
    {
      "title" : "Outcome Measure Time Frame",
      "code" : {
        "text" : "OutcomeMeasureTimeFrame"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
      }
    },
    {
      "title" : "Outcome Group List",
      "code" : {
        "text" : "OutcomeGroupList"
      },
      "section" : [{
        "title" : "Glucagon Nasal Powder",
        "code" : {
          "text" : "OG000"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
        },
        "entry" : [{
          "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
        }]
      },
      {
        "title" : "Glucagon Hydrochloride Solution",
        "code" : {
          "text" : "OG001"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
        },
        "entry" : [{
          "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
        }]
      }]
    },
    {
      "title" : "Outcome Class List",
      "code" : {
        "text" : "OutcomeClassList"
      },
      "section" : [{
        "title" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
        "code" : {
          "coding" : [{
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }]
        },
        "focus" : {
          "reference" : "EvidenceVariable/267228",
          "type" : "EvidenceVariable",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcome-1",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
        },
        "entry" : [{
          "reference" : "Evidence/267236",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-1--OG000",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "Evidence/267237",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-1--OG001",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
        }]
      }]
    }]
  },
  {
    "title" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
    "focus" : {
      "reference" : "EvidenceVariable/267229",
      "type" : "EvidenceVariable",
      "identifier" : {
        "type" : {
          "text" : "FEvIR Linking Identifier"
        },
        "system" : "https://fevir.net/FLI",
        "value" : "NCT03421379-secondaryOutcome-2",
        "assigner" : {
          "display" : "Computable Publishing LLC"
        }
      },
      "display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
    },
    "section" : [{
      "title" : "Outcome Measure Population Description",
      "code" : {
        "text" : "OutcomeMeasurePopulationDescription"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
      }
    },
    {
      "title" : "Outcome Measure Reporting Status",
      "code" : {
        "text" : "OutcomeMeasureReportingStatus"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
      }
    },
    {
      "title" : "Outcome Measure Time Frame",
      "code" : {
        "text" : "OutcomeMeasureTimeFrame"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
      }
    },
    {
      "title" : "Outcome Group List",
      "code" : {
        "text" : "OutcomeGroupList"
      },
      "section" : [{
        "title" : "Glucagon Nasal Powder",
        "code" : {
          "text" : "OG000"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
        },
        "entry" : [{
          "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
        }]
      },
      {
        "title" : "Glucagon Hydrochloride Solution",
        "code" : {
          "text" : "OG001"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
        },
        "entry" : [{
          "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
        }]
      }]
    },
    {
      "title" : "Outcome Class List",
      "code" : {
        "text" : "OutcomeClassList"
      },
      "section" : [{
        "title" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
        "code" : {
          "coding" : [{
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }]
        },
        "focus" : {
          "reference" : "EvidenceVariable/267229",
          "type" : "EvidenceVariable",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcome-2",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
        },
        "entry" : [{
          "reference" : "Evidence/267238",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-2--OG000",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "Evidence/267239",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-2--OG001",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
        }]
      }]
    }]
  },
  {
    "title" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
    "focus" : {
      "reference" : "EvidenceVariable/267230",
      "type" : "EvidenceVariable",
      "identifier" : {
        "type" : {
          "text" : "FEvIR Linking Identifier"
        },
        "system" : "https://fevir.net/FLI",
        "value" : "NCT03421379-secondaryOutcome-3",
        "assigner" : {
          "display" : "Computable Publishing LLC"
        }
      },
      "display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
    },
    "section" : [{
      "title" : "Outcome Measure Population Description",
      "code" : {
        "text" : "OutcomeMeasurePopulationDescription"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
      }
    },
    {
      "title" : "Outcome Measure Reporting Status",
      "code" : {
        "text" : "OutcomeMeasureReportingStatus"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
      }
    },
    {
      "title" : "Outcome Measure Time Frame",
      "code" : {
        "text" : "OutcomeMeasureTimeFrame"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
      }
    },
    {
      "title" : "Outcome Group List",
      "code" : {
        "text" : "OutcomeGroupList"
      },
      "section" : [{
        "title" : "Glucagon Nasal Powder",
        "code" : {
          "text" : "OG000"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
        },
        "entry" : [{
          "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
        }]
      },
      {
        "title" : "Glucagon Hydrochloride Solution",
        "code" : {
          "text" : "OG001"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
        },
        "entry" : [{
          "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
        }]
      }]
    },
    {
      "title" : "Outcome Class List",
      "code" : {
        "text" : "OutcomeClassList"
      },
      "section" : [{
        "title" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
        "code" : {
          "coding" : [{
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }]
        },
        "focus" : {
          "reference" : "EvidenceVariable/267230",
          "type" : "EvidenceVariable",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcome-3",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
        },
        "entry" : [{
          "reference" : "Evidence/267240",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-3--OG000",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "Evidence/267241",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-3--OG001",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
        }]
      }]
    }]
  },
  {
    "title" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration",
    "focus" : {
      "reference" : "EvidenceVariable/267231",
      "type" : "EvidenceVariable",
      "identifier" : {
        "type" : {
          "text" : "FEvIR Linking Identifier"
        },
        "system" : "https://fevir.net/FLI",
        "value" : "NCT03421379-secondaryOutcome-4",
        "assigner" : {
          "display" : "Computable Publishing LLC"
        }
      },
      "display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
    },
    "section" : [{
      "title" : "Outcome Measure Population Description",
      "code" : {
        "text" : "OutcomeMeasurePopulationDescription"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug and had evaluable PK data.</div>"
      }
    },
    {
      "title" : "Outcome Measure Reporting Status",
      "code" : {
        "text" : "OutcomeMeasureReportingStatus"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>"
      }
    },
    {
      "title" : "Outcome Measure Time Frame",
      "code" : {
        "text" : "OutcomeMeasureTimeFrame"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration</div>"
      }
    },
    {
      "title" : "Outcome Group List",
      "code" : {
        "text" : "OutcomeGroupList"
      },
      "section" : [{
        "title" : "Glucagon Nasal Powder",
        "code" : {
          "text" : "OG000"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
        },
        "entry" : [{
          "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
        }]
      },
      {
        "title" : "Glucagon Hydrochloride Solution",
        "code" : {
          "text" : "OG001"
        },
        "text" : {
          "status" : "generated",
          "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
        },
        "entry" : [{
          "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
        }]
      }]
    },
    {
      "title" : "Outcome Class List",
      "code" : {
        "text" : "OutcomeClassList"
      },
      "section" : [{
        "title" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)",
        "code" : {
          "coding" : [{
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }]
        },
        "focus" : {
          "reference" : "EvidenceVariable/267231",
          "type" : "EvidenceVariable",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcome-4",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration (NCT03421379)"
        },
        "entry" : [{
          "reference" : "Evidence/267242",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-4--OG000",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "Evidence/267243",
          "type" : "Evidence",
          "identifier" : {
            "type" : {
              "text" : "FEvIR Linking Identifier"
            },
            "system" : "https://fevir.net/FLI",
            "value" : "NCT03421379-secondaryOutcomeMeasure-4--OG001",
            "assigner" : {
              "display" : "Computable Publishing LLC"
            }
          },
          "display" : "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379"
        }]
      }]
    }]
  }]
}